
Compliance
Customers don't need to clear documents through internal review or negotiate confidentiality before running an analysis.
For law firms
Taimet is purpose-built for merger antitrust - a full analysis in 10-25 minutes, scored against six real-world regulatory outcome bands, with cited public sources your team can stand behind.
The first call with a client on a new deal requires a substantive view of the antitrust landscape - markets, overlaps, vertical exposure, enforcement posture. You know your client's business in depth. The gap is on the other side of the deal. Taimet closes that gap immediately - surfacing how the target operates, where overlaps actually sit, and how regulators are likely to view them - so your analysis starts complete, not asymmetric.
Taimet offers a full, structured antitrust analysis on every matter, in 10-25 minutes, using exclusively public sources, with verification throughout the pipeline and cited sources your team can check.
Expert-grade antitrust on public data - structured, cited, and ready for the client conversation.
Markets, competitive overlaps, vertical issues, state AG context, and enforcement history - in 10-25 minutes, on exclusively public sources. Structured like an enforcer's own analysis, not a chat transcript. Use it to prepare for the client call, route downstream work, or scope an HSR strategy.
The Taimet Score™ maps to six real-world regulatory outcome bands: early termination, pull and refile, second request, remedies, trial on the merits, adverse decision. When a client asks what to expect, the answer can be specific. A score of 51-70 means a second request is the likely outcome. 71-85 puts the deal in remedies territory. That prediction anchors the client conversation from day one.
Taimet sources its analysis from the public record: SEC filings, regulatory documents, trade publications, and news. When the analysis surfaces an overlap or vertical issue the team did not anticipate, the citations tell you where to look and what to confirm. Defensible sourcing for a report worth putting in the file.
Taimet pairs models deliberately: one to generate, one to interrogate. Claims are checked, reasoning is tested, and weak support is exposed before output is finalized. The result is analysis that has already been challenged before it reaches you, with citations that are also checked - so your team can do easier cite checking and you can speak with confidence.
Time is most valuable when it's defensible. Taimet provides a structured analytical foundation - so when your team goes deep, it's anchored in a consistent, comprehensive view of the market. The result is work that is easier to explain, support, and stand behind.
Clients don't just want analysis - they want conviction. Taimet equips your team with a clear view of the full transaction, including the less-visible regulatory dynamics, so your advice lands with precision and authority from the first conversation.
Every analysis produces a 0-100 Taimet Score™, mapped to six interpretive bands. The bands are designed to reflect the actual range of merger outcomes - from quick clearance through trial on the merits to adverse decision - as an experienced attorney would predict them.
Score Ranges
1–25Early termination
Parties may be granted early termination of the HSR waiting period when the transaction is unlikely to substantially lessen competition.
26–50Pull and refile
The merging parties can withdraw and refile to give enforcers more time, so review often extends beyond the usual 30-day window.
51–70Second request
These deals carry a higher risk of a second request and a longer review; toward the top of the band, negotiated outcomes become more common.
71–85Remedies
A complaint and structural or behavioral remedies are plausible, with lower scores leaning toward settlement and higher scores toward litigation.
86–95Trial on the merits
Substantial antitrust effects with few likely remedies can produce a litigated trial on the merits.
96–100Adverse decision
Strong anticompetitive concerns and limited remedies may lead to trial and an adverse decision against the merging parties.
1 to 25, Early termination: Parties may be granted early termination of the HSR waiting period when the transaction is unlikely to substantially lessen competition. 26 to 50, Pull and refile: The merging parties can withdraw and refile to give enforcers more time, so review often extends beyond the usual 30-day window. 51 to 70, Second request: These deals carry a higher risk of a second request and a longer review; toward the top of the band, negotiated outcomes become more common. 71 to 85, Remedies: A complaint and structural or behavioral remedies are plausible, with lower scores leaning toward settlement and higher scores toward litigation. 86 to 95, Trial on the merits: Substantial antitrust effects with few likely remedies can produce a litigated trial on the merits. 96 to 100, Adverse decision: Strong anticompetitive concerns and limited remedies may lead to trial and an adverse decision against the merging parties.
Taimet's Founder, Gwendolyn Lindsay Cooley, served nearly two decades as Wisconsin's Assistant Attorney General for Antitrust. She chaired the National Association of Attorneys General Multistate Antitrust Task Force, leading coalitions of state and federal enforcers and collaborating with international counterparts. She co-led the trial team for the States' challenge to T-Mobile/Sprint - one of the highest-profile telecom antitrust cases in recent history.
Most AI products are built by AI researchers who consult lawyers. Taimet was built by a lawyer who spent two decades doing this work, in partnership with an engineer with two decades building production software. The reasoning encoded into the system isn't theoretical. It's hers.
Read more about Gwendolyn's background →
There is a small body of working knowledge - the kind held by people who have spent years doing this - that determines how mergers actually get analyzed. None of it is in a textbook. Almost none of it is in an LLM's training data. All of it is in Taimet.
Small-molecule drugs are in the same market only if they share an identical molecular structure and are AB-rated for each other. Biologics are in the same market only if they’re biosimilars and treat the same disease. The distinction determines whether a pharma deal looks like a horizontal overlap or a non-issue. Most analysts don’t know it. Taimet does - and applies it automatically.
Different state attorneys general challenge different kinds of mergers. Some are aggressive on hospital consolidation. Others on agriculture. Others on tech. Taimet knows which jurisdictions are likely to act on which transactions, which state-level enforcement theories apply, and which mergers will draw multistate coalitions.
Pricing-power evidence often surfaces in investor presentations. Foreclosure intent shows up in board materials. Public statements about competitive intent surface in regulatory filings before they show up in press releases. Taimet knows where to look - because the person who designed it spent two decades looking there.
These are three examples among dozens. The full set is what makes the difference between an analysis that sounds expert and one that actually is.
Taimet identifies the transaction structure automatically - horizontal, vertical, conglomerate, cross-market, cluster market, private equity, or any combination. Most real deals involve more than one structure at once. A private equity roll-up in a health services market may face horizontal overlap, vertical foreclosure concerns, and cumulative competition effects simultaneously. The system applies the right analytical frameworks for each without the user needing to classify the deal first.
Companies with overlap in both product and geographic market, competing directly in the same space.
Companies in a direct or indirect vertical relationship within the same supply chain.
An acquisition in an unrelated industry, with no economic relationship between the companies.
Multiple products sold together as a bundle (e.g., supermarket goods, hospital services).
Companies selling identical products but operating in separate, non-overlapping geographic markets.
A private equity firm acquiring a company in a market where it has no existing holdings.
Across every industry
Both federal agencies build their enforcement staffs around industry teams. A human analyst has to choose what to know deeply. That structural constraint doesn't apply to Taimet. The same system that analyzes a pharmaceutical merger - where market definition turns on molecular structure and AB-rating - analyzes a semiconductor deal, a regional hospital consolidation, or a mining joint venture. No configuration required. For the first time, the analytical breadth of the entire merger landscape is available to a single analyst.
Taimet was designed first as an initial screening tool. For law firms, it produces structured market-overlap research that would otherwise take associates and paralegals days. Whether your team is preparing for a first client call, scoping an HSR strategy, or routing downstream work, Taimet delivers a substantive starting point in 10-25 minutes.
But Taimet stops where human judgment begins. Partners still advise clients and build the strategy. Associates still do research that makes every hour more grounded and defensible. The system is built to assist expert judgment, not replace it - and every output is designed to be reviewed, challenged, and built upon by the human in the loop.
Taimet doesn't accept uploads. We don't process party-supplied documents. We don't ingest deal materials. To run an analysis, the system needs only the names of the merging companies. This serves three purposes at once:

Customers don't need to clear documents through internal review or negotiate confidentiality before running an analysis.

No party-confidential data ever enters the system, which means none can leak from it.

Taimet can't be used as a sandbox to reverse-engineer which factors lower a score. The integrity of the analysis can't be manipulated.
Hallucination is the central problem with using general-purpose LLMs for high-stakes legal and economic analysis. The errors sound plausible. They're hard for a human reviewer to catch. And once a wrong claim enters the pipeline, downstream analysis builds on top of it.
Taimet addresses this with verification passes throughout the analysis. Citation-checking agents confirm that claims are actually supported by the cited sources. Reasoning-consistency checks compare conclusions across agents. Claims without source support are flagged. Different stages of the pipeline cross-validate each other before the report is finalized.
“When you are reviewing multiple transactions with a small team, the constraint isn't judgment, it's time. A tool like this does not replace discretion, but it immediately shows you where to focus it.”
“Reflecting the creator's experience of regulatory matters, the depth of analysis, and more importantly the consistency, is far beyond anything we've seen from general tools. It's genuinely useful for investment decisions.”
“Even as antitrust enforcement becomes less predictable, the need for a clear, consistent view of risk hasn't gone away - if anything, it's more important. Taimet is one of the few tools that brings real structure to that uncertainty. We've been early believers, and it's become a critical part of how we advise investors in live situations.”
“Taimet is the first tool I've seen that genuinely closes the gap between legal analysis and investor needs. It delivers clarity where there used to be noise, and it's quickly become indispensable to how we advise our clients.”
For law firms

